IDEXX LABORATORIES INC /DE Provision for Loan, Lease, and Other Losses
IDEXX LABORATORIES INC /DE (IDXX) reported Provision for Loan, Lease, and Other Losses of $6.27 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-04.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:ProvisionForLoanLeaseAndOtherLosses · last filed 2026-08-04
- IDEXX LABORATORIES INC /DE provision for loan, lease, and other losses for the quarter ending 2026-06-30 was $2.33M, a 58.64% increase year-over-year.
- IDEXX LABORATORIES INC /DE provision for loan, lease, and other losses for the quarter ending 2026-03-31 was $3.94M, a 36.40% increase year-over-year.
- IDEXX LABORATORIES INC /DE provision for loan, lease, and other losses for the quarter ending 2025-12-31 was $2.45M, a 37.10% increase year-over-year.
- IDEXX LABORATORIES INC /DE provision for loan, lease, and other losses for the quarter ending 2025-09-30 was $1.62M, a 21.09% increase year-over-year.
- IDEXX LABORATORIES INC /DE provision for loan, lease, and other losses for fiscal 2025 was $8.43M, a 22.75% increase from fiscal 2024.
- IDEXX LABORATORIES INC /DE provision for loan, lease, and other losses for fiscal 2024 was $6.87M, a 23.69% increase from fiscal 2023.
- IDEXX LABORATORIES INC /DE provision for loan, lease, and other losses for fiscal 2023 was $5.55M, a 4.75% decline from fiscal 2022.
- IDEXX LABORATORIES INC /DE provision for loan, lease, and other losses for fiscal 2022 was $5.83M, a 292.79% increase from fiscal 2021.
| Period end | Provision for Loan, Lease, and Other Losses 3 month | Provision for Loan, Lease, and Other Losses 6 month | Provision for Loan, Lease, and Other Losses 9 month | Provision for Loan, Lease, and Other Losses 12 month |
|---|---|---|---|---|
| 2026-06-30 | $2.33M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-04 | $6.27M 10-Q · filed 2026-08-04 | $8.72M derived: sum of 3 quarters · filed 2026-08-04 | $10.34M derived: sum of 4 quarters · filed 2026-08-04 |
| 2026-03-31 | $3.94M 10-Q · filed 2026-05-05 | $6.39M derived: sum of 2 quarters · filed 2026-05-05 | $8.01M derived: sum of 3 quarters · filed 2026-05-05 | $9.48M derived: sum of 4 quarters · filed 2026-08-04 |
| 2025-12-31 | $2.45M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-20 | $4.07M derived: sum of 2 quarters · filed 2026-02-20 | $5.54M derived: sum of 3 quarters · filed 2026-08-04 | $8.43M 10-K · filed 2026-02-20 |
| 2025-09-30 | $1.62M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-03 | $3.09M derived: sum of 2 quarters · filed 2026-08-04 | $5.98M 10-Q · filed 2025-11-03 | $7.77M derived: sum of 4 quarters · filed 2026-08-04 |
| 2025-06-30 | $1.47M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-04 | $4.36M 10-Q · filed 2026-08-04 | $6.15M derived: sum of 3 quarters · filed 2026-08-04 | $7.48M derived: sum of 4 quarters · filed 2026-08-04 |
| 2025-03-31 | $2.89M 10-Q · filed 2026-05-05 | $4.68M derived: sum of 2 quarters · filed 2026-05-05 | $6.01M derived: sum of 3 quarters · filed 2026-05-05 | $8.23M derived: sum of 4 quarters · filed 2026-05-05 |
| 2024-12-31 | $1.79M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-20 | $3.12M derived: sum of 2 quarters · filed 2026-02-20 | $5.34M derived: sum of 3 quarters · filed 2026-02-20 | $6.87M 10-K · filed 2026-02-20 |
| 2024-09-30 | $1.34M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-03 | $3.55M derived: sum of 2 quarters · filed 2025-11-03 | $5.08M 10-Q · filed 2025-11-03 | $5.17M derived: sum of 4 quarters · filed 2026-02-20 |
| 2024-06-30 | $2.21M derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-04 | $3.74M 10-Q · filed 2025-08-04 | $3.83M derived: sum of 3 quarters · filed 2026-02-20 | $5.44M derived: sum of 4 quarters · filed 2026-02-20 |
| 2024-03-31 | $1.53M 10-Q · filed 2025-05-01 | $1.62M derived: sum of 2 quarters · filed 2026-02-20 | $3.23M derived: sum of 3 quarters · filed 2026-02-20 | $4.76M derived: sum of 4 quarters · filed 2026-02-20 |
| 2023-12-31 | $88.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-20 | $1.70M derived: sum of 2 quarters · filed 2026-02-20 | $3.23M derived: sum of 3 quarters · filed 2026-02-20 | $5.55M 10-K · filed 2026-02-20 |
| 2023-09-30 | $1.61M derived: 10-Q 9 month − 10-Q 6 month · filed 2024-10-31 | $3.14M derived: sum of 2 quarters · filed 2024-10-31 | $5.46M 10-Q · filed 2024-10-31 | $6.18M derived: sum of 4 quarters · filed 2025-02-21 |
| 2023-06-30 | $1.53M derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-06 | $3.86M 10-Q · filed 2024-08-06 | $4.57M derived: sum of 3 quarters · filed 2025-02-21 | $6.33M derived: sum of 4 quarters · filed 2025-02-21 |
| 2023-03-31 | $2.33M 10-Q · filed 2024-05-01 | $3.04M derived: sum of 2 quarters · filed 2025-02-21 | $4.80M derived: sum of 3 quarters · filed 2025-02-21 | $6.06M derived: sum of 4 quarters · filed 2025-02-21 |
| 2022-12-31 | $717.00K derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-21 | $2.47M derived: sum of 2 quarters · filed 2025-02-21 | $3.74M derived: sum of 3 quarters · filed 2025-02-21 | $5.83M 10-K · filed 2025-02-21 |
| 2022-09-30 | $1.75M derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-01 | $3.02M derived: sum of 2 quarters · filed 2023-11-01 | $5.11M 10-Q · filed 2023-11-01 | $4.88M derived: sum of 4 quarters · filed 2024-02-22 |
| 2022-06-30 | $1.27M derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-01 | $3.36M 10-Q · filed 2023-08-01 | $3.12M derived: sum of 3 quarters · filed 2024-02-22 | $4.07M derived: sum of 4 quarters · filed 2024-02-22 |
| 2022-03-31 | $2.09M 10-Q · filed 2023-05-02 | $1.86M derived: sum of 2 quarters · filed 2024-02-22 | $2.81M derived: sum of 3 quarters · filed 2024-02-22 | $3.39M derived: sum of 4 quarters · filed 2024-02-22 |
| 2021-12-31 | -$235.00K derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-22 | $716.00K derived: sum of 2 quarters · filed 2024-02-22 | $1.30M derived: sum of 3 quarters · filed 2024-02-22 | $1.48M 10-K · filed 2024-02-22 |
| 2021-09-30 | $951.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-01 | $1.53M derived: sum of 2 quarters · filed 2022-11-01 | $1.72M 10-Q · filed 2022-11-01 | $1.43M derived: sum of 4 quarters · filed 2023-02-16 |
| 2021-06-30 | $582.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-02 | $768.00K 10-Q · filed 2022-08-02 | $479.00K derived: sum of 3 quarters · filed 2023-02-16 | $362.00K derived: sum of 4 quarters · filed 2023-02-16 |
| 2021-03-31 | $186.00K 10-Q · filed 2022-05-04 | -$103.00K derived: sum of 2 quarters · filed 2023-02-16 | -$220.00K derived: sum of 3 quarters · filed 2023-02-16 | $903.00K derived: sum of 4 quarters · filed 2023-02-16 |
| 2020-12-31 | -$289.00K derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-16 | -$406.00K derived: sum of 2 quarters · filed 2023-02-16 | $717.00K derived: sum of 3 quarters · filed 2023-02-16 | $4.95M 10-K · filed 2023-02-16 |
| 2020-09-30 | -$117.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-02 | $1.01M derived: sum of 2 quarters · filed 2021-11-02 | $5.24M 10-Q · filed 2021-11-02 | $5.28M derived: sum of 4 quarters · filed 2022-02-16 |
| 2020-06-30 | $1.12M derived: 10-Q 6 month − 10-Q 3 month · filed 2021-07-30 | $5.35M 10-Q · filed 2021-07-30 | $5.40M derived: sum of 3 quarters · filed 2022-02-16 | $5.71M derived: sum of 4 quarters · filed 2022-02-16 |
| 2020-03-31 | $4.23M 10-Q · filed 2021-05-04 | $4.27M derived: sum of 2 quarters · filed 2022-02-16 | $4.59M derived: sum of 3 quarters · filed 2022-02-16 | $4.53M derived: sum of 4 quarters · filed 2022-02-16 |
| 2019-12-31 | $44.00K derived: 10-K 12 month − 10-Q 9 month · filed 2022-02-16 | $363.00K derived: sum of 2 quarters · filed 2022-02-16 | $297.00K derived: sum of 3 quarters · filed 2022-02-16 | $662.00K 10-K · filed 2022-02-16 |
| 2019-09-30 | $319.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2020-10-29 | $253.00K derived: sum of 2 quarters · filed 2020-10-29 | $618.00K 10-Q · filed 2020-10-29 | |
| 2019-06-30 | -$66.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2020-07-31 | $299.00K 10-Q · filed 2020-07-31 | ||
| 2019-03-31 | $365.00K 10-Q · filed 2020-04-30 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Lantheus Holdings, Inc. (LNTH) | United States | $6.510B | 26.31 |
| NEOGEN CORP (NEOG) | United States | $2.979B | -247.49 |
| Celldex Therapeutics, Inc. (CLDX) | United States | $2.471B | -9.72 |
| Intellia Therapeutics, Inc. (NTLA) | United States | $1.705B | -5.92 |
| ACHIEVE LIFE SCIENCES, INC. (ACHV) | United States | $0.806B | -5.88 |
| QuidelOrtho Corp (QDEL) | United States | $0.733B | -0.90 |
| Alpha Teknova, Inc. (TKNO) | United States | $0.500B | -18.12 |
| MYRIAD GENETICS INC (MYGN) | United States | $0.397B | -4.84 |
| Insight Molecular Diagnostics Inc. (IMDX) | United States | $0.129B | -3.90 |
| IMMUCELL CORP /DE/ (ICCC) | United States | $0.091B | 116.10 |